Physician profile
Mallory Jo Gray
NPI 1255963252
$2,304.43
in general payments reported to CMS, 2019-2025
20 companies · $954 in 2025
The $954 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $279 · 2023: $431 · 2024: $640 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $962.21 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $204.37 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $148.98 | 2023-2025 | Rexulti, Abilify Maintena |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.68 | 2022-2023 | Lifevest |
| Novo Nordisk INC | $138.86 | 2022-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $116.56 | 2023-2024 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Collegium Pharmaceutical, INC. | $90.51 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $75.90 | 2025 | Fanapt |
| Corcept Therapeutics | $68.14 | 2025 | Korlym |
| Ironshore Pharmaceuticals INC. | $58.79 | 2024 | |
| Pfizer INC. | $54.71 | 2025 | |
| Boston Scientific Corporation | $53.57 | 2022-2023 | Watchman Access System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.50 | 2025 | Caplyta |
| Organon LLC | $34.64 | 2025 | Nexplanon |
| Seqirus USA INC | $22.23 | 2024 | Flucelvax, Fluad |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.29 | 2022 | |
| Sobi, INC | $16.67 | 2022 | |
| Mylan Specialty L.P. | $15.75 | 2023 | Yupelri |
| Phathom Pharmaceuticals, INC. | $14.79 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $14.28 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.